WO2023213854 - CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR.
National phase entry:
Publication Number
WO/2023/213854
Publication Date
09.11.2023
International Application No.
PCT/EP2023/061626
International Filing Date
03.05.2023
Title **
[English]
CRYSTALLINE FORM OF 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZIN-3-YLCARBAMOYL)-6 AZASPIRO[2.5]OCTANE-6-CARBOXYLATE AS MONOACYLGLYCEROL LIPASE INHIBITOR.
[French]
FORME CRISTALLINE DE 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-YL (S)-1-(PYRIDAZINE-3-YLCARBAMOYL)-6 AZASPIRO [2,5] OCTANE-6-CARBOXYLATE EN TANT QU'INHIBITEUR DE LA MONOACYLGLYCÉROL LIPASE
Applicants **
H. LUNDBECK A/S
Inventors
VETTER, Thomas
WIENER, John J.M.
GRICE, Cheryl A.
BUZARD, Daniel J.
CISAR, Justin S.
WEBER, Olivia D.
ALLAN, Amy
RAFFAELE, Nicholas
MOODY, Jeanne V.
SHAGHAFI, Michael B.
Priority Data
63/338,252
04.05.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2093 | |
| EPO | Filing, Examination, Granting | 8336 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,995
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein is new crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl (S)-1- (pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.[French]
L'invention concerne de nouvelles formes cristallines de l'inhibiteur de MAGL 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazine-3-ylcarbamoyl)-6-azaspiro [2,5] octane-6-carboxylate.